FDA's analysis of the EMPA-REG OUTCOME data for Boehringer Ingelheim GMBH and Eli Lilly & Co.'s typed 2 diabetes drug Jardiance (empagliflozin) reflects the limits of how far a single study designed for safety purposes can be stretched to support efficacy claims.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?